Safety aspects of parenteral iron supplementation therapies in patients with chronic kidney disease;Sicherheitsaspekte parenteraler Eisentherapien bei Patienten mit chronischer Niereninsuffizienz

Deutsche Medizinische Wochenschrift

Volumn 138, Issue 24, 2013, Pages 1312-1317

  Potthoff, S A ^a   Munch H G ^b  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b Nierenzentrum Wesseling ^*  (Germany)

Author keywords

chronic kidney disease; iron deficiency; parenteral iron therapy

Indexed keywords

IRON;

ARTICLE; CHRONIC KIDNEY DISEASE; HUMAN; IRON THERAPY; PATIENT SAFETY;

ADMINISTRATION, ORAL; ANAPHYLAXIS; ANEMIA, IRON-DEFICIENCY; DISACCHARIDES; FERRIC COMPOUNDS; FERUMOXYTOL; GLUCARIC ACID; HUMANS; INFUSIONS, INTRAVENOUS; IRON COMPOUNDS; IRON-DEXTRAN COMPLEX; KIDNEY FAILURE, CHRONIC; MALTOSE; OXIDATIVE STRESS; RENAL DIALYSIS;

EID: 84878780467     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0033-1343219     Document Type: Article

References (40)

1. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Intern Suppl: 2012; 2 04
2. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis: 2006; 47 5 Suppl 03 S11 145
3. NICE Clinical guideline 114 Anaemia management in people with chronic kidney disease. 2011; http://guidance.nice.org.uk/CG114 (Letzter Zugriff: 13.05.2013)
4. Agarwal R., Vasavada N., Sachs N. G. et al. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int: 2004; 65 2279 2289 (Pubitemid 38670014)
5. Anirban G., Kohli H. S., Jha V. et al. The comparative safety of various intravenous iron preparations in chronic kidney disease patients. Ren Fail: 2008; 30 629 638
6. Auerbach M., Ballard H. Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program: 2010; 2010 338 347
7. Auerbach M., Coyne D., Ballard H. Intravenous iron: from anathema to standard of care. Am J Hematol: 2008; 83 580 588 (Pubitemid 351874877)
8. Balakrishnan V. S. et al. Physicochemical properties of ferumoxytol, a new intravenous iron preparation. Eur J Clin Invest: 2009; 39 489 496
9. Canavese C. et al. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int: 2004; 65 1091 1098 (Pubitemid 38251085)
10. Coppol E. et al. A comparative look at the safety profiles of intravenous iron products used in the hemodialysis population (February). Ann Pharmacother: 2011; 25 241 247
11. Eschbach J. W. Iron requirements in erythropoietin therapy. Best Pract Res Clin Haematol: 2005; 18 347 361 (Pubitemid 40298374)
12. Ferrari P., Kulkarni H., Dheda S. et al. Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol: 2011; 6 77 83
13. Gozzard D. When is high-dose intravenous iron repletion needed? Assessing new treatment options. Drug Des Devel Ther: 2011; 5 51 60
14. Haddad A., Abbadi R., Marji A. Use of iron sucrose in dialysis patients sensitive to iron dextran. Saudi J Kidney Dis Transpl: 2009; 20 208 211
15. Hayat A. Safety issues with intravenous iron products in the management of anemia in chronic kidney disease. Clin Med Res: 2008; 6 93 102
16. Horl W. H. Clinical aspects of iron use in the anemia of kidney disease. J Am Soc Nephrol: 2007; 18 382 393 (Pubitemid 46193303)
17. Jahn M. R. et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm: 2011; 78 480 491
18. Kosch M. et al. A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo. Nephrol Dial Transplant: 2001; 16 1239 1244 (Pubitemid 32547381)
19. Locatelli F. et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant: 2004; 19 Suppl 02 ii1 47
20. Lu M., Cohen M. H., Rieves D. et al. FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol: 2010; 85 315 319
21. Macdougall I. C. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous? Curr Med Res Opin: 2010; 26 473 482
22. Macdougall I. C., McLaughlin J., Fortin G. S., Li Z., Strauss W. E. The FIRST Head-to-Head Comparison Study (Ferumoxytol Compared to Iron Sucrose Trial) of the Safety and Efficacy of Ferumoxytol Compared with Iron Sucrose for the Treatment of Iron Deficiency Anemia in Patients with Chronic Kidney Disease. [Poster presented at the American Society of Nephrology Kidney Week 2011; November 8-13, 2011] Philadelphia, PA: 2011
23. Malindretos P. et al. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran. Am J Nephrol: 2007; 27 572 579 (Pubitemid 350014944)
24. McCormack P. L. Ferumoxytol: in iron deficiency anaemia in adults with chronic kidney disease. Drugs: 2012; 72 2013 2022
25. Mikhail A., Shrivastava R., Richardson D. UK Renal Association Clinical Practice Guidelines Anemia of CKD. (5th edition). 2010; http://www.renal.org/ clinical/guidelinessection/AnaemiaInCKD.aspx (Letzer Zugriff: 24.05.2013)
26. Moniem K. A., Bhandari S. Tolerability and efficacy of parental iron therapy in hemodialysis patients, a comparison of preparations. Transfusion Altern Transfusion Med: 2007; 9 37 42
27. Munoz M., Garcia-Erce J. A., Remacha A. F. Disorders of iron metabolism. Part II: iron deficiency and iron overload. J Clin Pathol: 2011; 64 287 296
28. Pai A. B. et al. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis. Pharmacotherapy: 2007; 27 343 350 (Pubitemid 46327902)
29. Pai A. B. et al. Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose. Biometals: 2011; 24 603 613
30. Qunibi W. Y. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review. Arzneimittelforschung: 2010; 60 399 412
31. Rostoker G. et al. Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. Am J Med: 2012; 125 991 999
32. Santosh S., Podaralla P., Miller B. Anaphylaxis with elevatedserum tryptase efter administration of intravenous ferumoxytol. Nephrology Dialysis Transplantation Plus: 2010; 1 2
33. Sav T. et al. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran? Ren Fail: 2007; 29 423 426 (Pubitemid 46752324)
34. Sheashaa H., El-Husseini A., Sabry A. et al. Parenteral iron therapy in treatment of anemia in end-stage renal disease patients: a comparative study between iron saccharate and gluconate. Nephron Clin Pract: 2005; 99 c97 101
35. Siddique A., Kowdley K. V. Review article: the iron overload syndromes. Aliment Pharmacol Ther: 2012; 35 876 893
36. Spada P. L. et al. Ferritin iron content in haemodialysis patients: comparison with septic and hemochromatosis patients. Clin Biochem: 2008; 41 997 1001
37. Stefansson B. V., Haraldsson B., Nilsson U. Acute oxidative stress following intravenous iron injections in patients on chronic hemodialysis: A comparison of iron-sucrose and iron-dextran. Nephron Clin Pract: 2011; 118 c250 c257
38. Van Wyck D. B. et al. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. Am J Kidney Dis: 2000; 36 88 97 (Pubitemid 30432569)
39. Van B. P. et al. Iron overdose: a contributor to adverse outcomes in randomized trials of anemia correction in CKD. Int Urol Nephrol: 2012; 44 499 507
40. Zanen A. L. et al. 'Oversaturation' of transferrin after intravenous ferric gluconate (Ferrlecit(R)) in haemodialysis patients. Nephrol Dial Transplant: 1996; 11 820 824